Corvus Pharmaceuticals, Inc. CRVS
9.83 USD +0.13 (+1.34%)
At closeNov 3, 2026, 5:00 PM EST
9.98 +0.15 +1.57%
After hours · Nov 3, 5:00 PM ET
9.73 Day range 10.06
6.39 52-week range 26.95
- YTD
- +27.66%
- 1 year
- +27.99%
Analyst view
Price target (mean) 33.14 +237.2% upside
Now 9.83
- Target (low)
- 27.00
- Target (mean)
- 33.14
- Target (high)
- 42.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.205 | -0.22 – -0.18 | -0.12 | -70.8% | 0 | 0.0% | 4 |
| Next quarter | -0.2275 | -0.25 – -0.18 | -0.15 | -51.7% | 0 | 0.0% | 4 |
| Current year | -0.7775 | -0.81 – -0.71 | -0.5373 | -44.7% | 0 | 0.0% | 4 |
| Next year | -1.07 | -1.28 – -0.83 | -0.7775 | -37.3% | 4.55M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | Initiated | — | Buy |
| Mar 13, 2026 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jan 22, 2026 | Jefferies | Maintained | Buy | Buy |
| Jan 21, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Jan 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 13, 2025 | Barclays | Initiated | — | Overweight |
| May 20, 2025 | Mizuho | Maintained | Outperform | Outperform |
| May 9, 2025 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 26, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 26, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 14, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 2, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 13, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Sep 16, 2024 | Ladenburg Thalmann | Maintained | Buy | Buy |
| May 7, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 1, 2024 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Mar 27, 2024 | Mizuho | Maintained | Neutral | Neutral |
| Mar 20, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 7, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 16, 2023 | Mizuho | Reiterated | Neutral | Neutral |
| May 30, 2023 | Ladenburg Thalmann | Maintained | Buy | Buy |
| May 9, 2023 | Cantor Fitzgerald | Maintained | — | Overweight |
| Mar 30, 2023 | Mizuho | Reiterated | — | Neutral |
| Oct 7, 2022 | Ladenburg Thalmann | Initiated | — | Buy |
| Dec 3, 2021 | Cantor Fitzgerald | Maintained | — | Overweight |
| Dec 1, 2021 | Jefferies | Initiated | — | Buy |
| Aug 3, 2021 | Mizuho | Maintained | — | Neutral |
| Jul 16, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| May 27, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |